Form 4: Evolent Health Director Springstubb Acquires 15,000 Shares

Director Brendan B Springstubb purchased 15,000 shares of Evolent Health, Inc. at an average price of $9.27 on March 7, 2025.

Summary

• On March 7, 2025, Brendan B Springstubb, a director of Evolent Health, Inc., acquired 15,000 shares of Class A Common Stock.
• The shares were purchased at a weighted average price of $9.27.
• Following the transaction, Springstubb directly owns 26,842 shares, which includes restricted stock units granted under previous awards.
• The reporting person is willing to provide full information regarding the number of shares purchased at each separate price within the range of $9.13-$9.45 upon request.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's performance.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency into their investment decisions.

Stakeholder Impact

• The purchase could have a minor positive impact on shareholder sentiment.

Key Dates